Search results
FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia
Pharmaceutical Technology via Yahoo Finance· 15 hours agoThe US Food and Drug Administration (FDA) has approved Amgen’s BLINCYTO (blinatumomab) for...
Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment
Investor's Business Daily· 3 hours agoNurix's approach degrades a protein called BTK. Doing so blocks defective B cells, which can drive...
...STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or...
Morningstar· 2 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma ...
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Zacks via Yahoo Finance· 9 hours agoRoche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 15 hours agoFate Therapeutics is also advancing its Phase I study of ADR-armed FT522 (CD19 CAR-INK) for patients...
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
Pharmaceutical Technology via Yahoo Finance· 3 hours agoIt covalently binds a cysteine residue (Cys481) in the BTK active site and inhibits BTK enzymatic...
Pfizer reports data from Phase II multiple myeloma treatment trial
Clinical Trials Arena via Yahoo Finance· 15 hours agoPfizer has announced findings from the Phase II MagnetisMM-3 clinical trial of ELREXFIO...
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday? - Mustang Bio (NASDAQ:MBIO)
Benzinga· 10 hours agoMB-106 is being developed in a collaboration between Mustang and Fred Hutch Cancer Center to treat...
EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma
Clinical Trials Arena via Yahoo Finance· 8 hours agoFollicular lymphoma (FL) is a chronic disease that accounts for about 20% of non-Hodgkin's lymphoma...
Biotest wins FDA approval for plasma protein therapy
Pharmaceutical Technology via Yahoo Finance· 7 hours agoAntibody deficiency syndrome is caused by an immunoglobulin level significantly under the standard range or a failure of immunoglobulin function. The...
